IAVI-led candidates
Our pipeline shows the progress we and our partners are making on products in development for priority infectious diseases. For information on programs where IAVI is a key partner, visit our pipeline of IAVI-supported candidates. For an explanation of development phases, visit our clinical development page.
Pipeline: IAVI-supported candidatesHIV vaccine & antibody candidates
eOD-GT8 60mer mRNA + Core-g28v2 60mer mRNA
HIVPartners
Bill & Melinda Gates Foundation; Collaboration for AIDS Vaccine Discovery Vaccine Immunology Statistical Center; Duke University; Emory University; Fred Hutchinson Cancer Center; George Washington University; Moderna; Scripps Research; United States Institutes of Health Vaccine Research Center; University of Texas San Antonio
eOD-GT8 60mer mRNA
HIVPartners
Aurum Institute (Tembisa, South Africa); Bill & Melinda Gates Foundation; Center for Family Health Research (Kigali, Rwanda); Moderna; Scripps Research; United States Agency for International Development
rVSVΔG-Env-HIV
HIVPartners
Government of Japan
Triple antibody combination product
HIVPartners
Scripps Research; United States Agency for International Development; United States National Institutes of Health (NIAID/DAIDS/VRC) and its clinical trial networks (HVTN/HPTN/IMPAACT)
Emerging infectious diseases vaccine candidates
rVSVΔG-LASV-GPC
Lassa virusPartners
Batavia Biosciences; Bernhard Nocht Institute (Phase 2b); Brigham and Women’s Hospital (Phase 1); Charles River Laboratories; CliniOps; Coalition for Epidemic Preparedness; East West Medical Research Institute (Phase 1); EpiCentre; European & Developing Countries Clinical Trials Partnership; George Washington University (Phase 1); International Vaccine Institute; IQVIA; Irrua Specialist Teaching Hospital (Phase 2b); La Jolla Institute for Immunology; Kenema Government Hospital; Medical Research Council – Gambia; Merck Advisory Group; NeoGenomics Laboratories; Noguchi Memorial Institute for Medical Research, Ghana (Phase 2); Pharmalys; Phebe Hospital (Phase 2b); PREVAIL JFK Hospital Liberia (Phase 2a and 2b); PREVAIL Redemption Hospital (Phase 1); Public Health Agency of Canada; Seattle Children’s Research Institute; Tulane University; University of Liberia (Phase 2b); University of North Carolina Project Liberia (Phase 2b); University of Texas Medical Branch at Galveston; Walter Reed Program, Nigeria (Phase 2)
rVSV∆G-SEBOV-GP
Sudan virusPartners
Batavia Biosciences; Battelle; Biomedical Advanced Research and Development Authority (BARDA); BioReliance; Boston University’s National Emerging Infectious Diseases Laboratories; Charles River Laboratories; Imperial College London; IQVIA; La Jolla Institute for Immunology; Merck Advisory Group; NeoGenomics Laboratories; Public Health Agency of Canada; Seattle Children’s Research Institute; Tulane University; University of Texas Medical Branch at Galveston; Viral Hemorrhagic Fever Consortium
rVSV∆G-MARV-GP
Marburg virusPartners
Batavia Biosciences; Battelle; Biomedical Advanced Research and Development Authority; Charles River Laboratories; Imperial College London; IQVIA; La Jolla Institute for Immunology; Merck Advisory Group; Public Health Agency of Canada; Seattle Children’s Research Institute; Texas Biomedical Research Institute; University of Texas Medical Branch at Galveston; Viral Hemorrhagic Fever Consortium
Tuberculosis (TB) vaccine candidates
MTBVAC
TuberculosisPartners
Bill & Melinda Gates Foundation; Biofabri S.L.; Open Philanthropy; Universidad de Zaragoza
mRNA-encoded TB antigens
TuberculosisPartners
Moderna; Trudeau Institute; U.S. National Institute of Allergy and Infectious Diseases; U.S. National Institutes of Health; University of Georgia